Earnings per share for the last twelve months: Ascentage Pharma Group International (AAPG)
Ascentage Pharma Group develops oncology drugs in the US and China, focusing on resistant forms of cancer. This daily chart from GURU.Markets illustrates earnings per share over the last 12 months, where the value -2.28 captures this metric. Proprietary molecules with high demand inertia ensure stable income, while the global expansion of Olverembatinib guarantees full patient retention.
Metric breakdowns and analytics for Ascentage (AAPG)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Equity Ascentage Pharma Group|AAPG - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital ascentage.com|AAPG - Company Total Debt|Debts to Book Capitalization Ascentage Pharma Group|AAPG - Long-Term Debt|Company Short-Term Debt Ascentage Pharma|Quick Liquidity Indicator ascentage.com
- net income and valuation multiples indicators:
AAPG - Profit After Payment of Taxes|Projected Future Earnings Ascentage Pharma Group|AAPG - P/E Multiple|Forward P/E Multiple Ascentage Pharma Group International|AAPG - Price to Net Income Growth Ratio|EV/EBITDA Multiple Ascentage Pharma Group|AAPG - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Ascentage Pharma|AAPG - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months ascentage.com|AAPG - Earnings per share trend in current year|Earnings growth forecast for next year Ascentage Pharma Group
- revenue and sales proceeds data:
Initial company analysis:Ascentage Pharma Corp (AAPG)
This indicator determines the investment reliability of Ascentage Pharma Group by calculating the portion of net income attributable to a single ordinary share over the last 12 months. The current value of -2.28 for the annual earnings per share reflects the efficiency of innovation capitalization, including the implementation of AI models and robotic bio-screening to accelerate the development of anti-tumor drugs.
Main competitors
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|CG Oncology Corp - Earnings per share for the trailing year|URGN (UroGen Pharma Ltd) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Bicara Therapeutics Inc. BCAX|Earnings per share for the last twelve months Personalis, Inc. (PSNL)|ERAS - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) DCTH (delcath.com)|Net earnings per share for the trailing year Y-mAbs Corp|AURA - Earnings per share for the last twelve months|CADL (candeltx.com) - Earnings per share for the last 12 months|ARAY (accuray.com) - Net earnings per share for the last 12 months|SELLAS Life Sciences Group Inc. (SLS) - Net earnings per share (EPS TTM)|ACTU (Actuate Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Citius Oncology Inc|Net earnings per share (EPS TTM) HURA|TARA (Protara Therapeutics) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) FATE (Fate Therapeutics)|Net earnings per share for the last four quarters Aadi Bioscience Inc (WHWK)|TScan Therapeutics, Inc. - Net earnings per share (EPS TTM)|CSBR (Champions Oncology, Inc.) - Earnings per share for the last 12 months|XBIT (XBiotech USA) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months CEL-SCI Corp (CVM)|OSTX (OS Therapies Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Radiopharm Theranostics (RADX)|Net earnings per share for the last 12 months ARTV (Artiva Biotherapeutics, Inc.)|ANL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Veru Inc. VERU|Earnings per share for the trailing year TPST|XLO: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Renovaro RENB|MURA (muraloncology.com) - Net earnings per share for the last 12 months|Kairos Pharma Inc - Earnings per share for the trailing year|Net earnings per share for the last 12 months OKUR|Net earnings per one share for the last twelve months CytoMed Therapeutics Limited GDTC|Net earnings per share (EPS TTM) CRIS|Net earnings per share (EPS TTM) Apollomics Inc. (APLM)|Net earnings per share (EPS TTM) THAR (Tharimmune Corp)|Net earnings per share for the last four quarters Advanced Biomed Inc (ADVB)|Genprex Inc - Net earnings per share (EPS TTM)|CLDI - Net earnings per share (EPS TTM)|Sunshine Biopharma Inc. (SBFM) - Earnings per share for the last twelve months|XBIO - Net earnings per share for the last four quarters|SLRX (Salarius Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kitov Pharma|Net earnings per share for the last 12 months AONC (American Oncology Network)|BGNE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics Inc.)|Elevation Oncology, Inc. - Earnings per share for the last twelve months|ICAD - Earnings per share for the last twelve months|IKNA - Net earnings per share (EPS TTM)|Notable Labs (NTBL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
